Bronchiolitis: the European Medicines Agency authorizes the first vaccine for babies

This respiratory syncytial virus (RSV) is highly contagious and can lead to severe ailments such as pneumonia and bronchiolitis, resulting in thousands of deaths and mass hospitalizations across the world. The vaccine named “Abrysvo“constitutes a major breakthrough, being the first vaccine indicated for the passive immunization of infants, given to babies from birth up to 6 months, following administration of the vaccine to the mother during pregnancy. At the same time, it is also intended for the active immunization of adults aged 60 years and over. As RSV is one of the main causes of pediatric hospitalization in Europe, it was priority to develop a vaccine or other preventive treatment. This vaccine was therefore evaluated with celerity within the framework of the EMA fast track review mechanism, because of its importance to public health. Respiratory syncytial virus is usually associated with mild cold-like symptoms, but it can have serious consequences in young children and the elderly (source 1).

EMA’s decision will now be submitted to the European Commission for marketing authorization within the European Union, a step normally considered quick and logical depending on the procedure.